U.S. Pa Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collec-

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT
(Not for submission under 37 CFR 1.99)
(,

Application Number		10559617			
Filing Date		2006-05-26			
First Named Inventor	DOMINIQUE GUENIN				
Art Unit		3732			
Examiner Name					
Attornov Docket Number		GLIENIN-1365			

	U.S.PATENTS				Remove					
Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue Date	ue Date Name of Patentee or Applicant of cited Document		Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear			
	1	4619012		1986-10-28		WACHTEL				
	2	5327611		1994-07-12		BALSTER				
If you wis	h to a	dd additional U.S. Pate	ent citatio	n informatio	n pi	lease click the	Add button.	_	Add	
			U.S.P	ATENT AP	PLK	CATION PUB	LICATIONS		Remove	
Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publication Date	1	Name of Patentee or Applicant of cited Document		Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear		
	1	20020112362	A1	2002-08-22		CORREA				
If you wisl	h to a	l dd additional U.S. Pub	lished Ap	plication cit	ation	n information	please click the Ad	d butto	n. Add	
				FOREIGN	PAT	ENT DOCUM	IENTS		Remove	
Examiner Initial*	Cite No	Foreign Document Number ³			nd ode4	Publication Date	Name of Patente Applicant of cited Document		Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear	TG
	1	1553261	GB			1979-09-26	ETABLISSEMENT: LARDENOIS S.A.	s		
	2	0103205	EP	A1		1984-03-21	BRAUN AKTIENGESELLSI	CHAFT		

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		10559617		
Filing Date		2006-05-26		
First Named Inventor	DOMINIQUE GUENIN			
Art Unit		3732		
Examiner Name				
Attorney Docket Number		GUENIN-1365		

	3	0141532	EP	A1	1985-05-15	DENROY PLASTICS LIMITED		
	4	2577774	FR	A1	1986-08-29	WACHTEL		
If you wis	h to a	dd additional Foreign	Patent Document	citation	information pl	lease click the Add butto	n Add	
			NON-PATE	NT LITE	ERATURE DO	CUMENTS	Remove	
Examiner Initials*	Examiner Cite include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, pages(s), volume-issue number(s), publisher, city and/or country where published.						Ţŝ	
1								
If you wish to add additional non-patent literature document citation information please click the Add button Add								
EXAMINER SIGNATURE								
Examiner	Signa	ture				Date Considered		
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.								

1 See Knd. Codes of USPTO Plant Documents at year, USPTO, DOLY or MPEP 901.04. Feater office in the issued for document, by the two-leter code (WIPO) Standard 573.3. Froughease parted convenents, the induction of the year of the reight of the Eigener must precede the sent in under the parted to country. Mixed of coursent by the appropriate symbols as indicated on the document without the parted to country. Wird of coursent by the appropriate symbols as indicated on the document without WIPO Standard 57.16 if possible. 3 Applicant is to place a check mark here it English teaquage streated in a standard.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		10559617		
Filing Date		2006-05-26		
First Named Inventor	DOMINIQUE GUENIN			
Art Unit		3732		
Examiner Name				
Attorney Docket Number		GUENIN-1365		

CERTIFICATION STATEMENT

Please see 37	CFR 1.97 a	d 1.98 to make the	appropriate selection(s):
---------------	------------	--------------------	---------------------------

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(1).

OR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(2).

- See attached certification statement.
- Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature

Signature	/William H Holt/	Date (YYYY-MM-DD)	2007-02-12					
Name/Print	William H. Holt	Registration Number	20766					

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office U.S. Department of Commerce P.O. Box 1450, Alexandria VA 22313-1450, DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria. VA 22313-1450.

Privacy Act Statement

The Privacy Act of 1974 (P. L. 93-579) requires that you be given certain information in connection with your submission of the stackhold from related to a patient application or patient. Accordingly, pursuant to the requirements of the Act, places be advised that (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) familishing of the information solicided is couldrain; and (3) the primoral pursuance for which the information is used by the U.S. Patient and Trademan Coffice is to process and/or examine your submission related to a patient agricultant or patient. If you do not furnish the requested process and/or examine your submission related to a patient agricultant or patient. If you do not furnish the requested results of the patient of the patient and the patient of the patient

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
 - A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiation.
 - A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
 - A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552(m).
 - A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
 may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
 to the Patent Cooperation Treaty.
 - A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
 - 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designed, uturing an insection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 4d U.S.C. 2904 and 2905. Such disclosure shall be made in accordance with the GSA requisions governing inseption of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
- A record from this system of records may be disclosed, as a routine use, to the public after either publication of the
 application pursuant to 35 U.S.C. 12(2) to rissuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be
 disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filled in application
 which became abandoned or in which the proceedings were terminated and which application is referenced by either a
 published application, an application open to public inspections or as issued patent.
 - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.